Class Ic antiarrhythmic drugs and structural heart disease—Time for a randomized controlled study?
- 5 March 2026
- journal article
- Published by Elsevier in Heart Rhythm
- Vol. 23 (8) , e1385-e1386
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: A systematic reviewHeart Rhythm, 2026
- ECTOPIC trial: The efficacy of flEcainide Compared To metOprolol in reducing Premature ventrIcular Contractions: A randomized open-label crossover study in pediatric patientsHeart Rhythm, 2024
- Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-DefibrillatorsJACC: Clinical Electrophysiology, 2024
- CAST: A study that rocked the cardiology world and became the poster child for evidence-based medicineHeart Rhythm, 2024
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial FibrillationJACC, 2023
- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary DiseaseJACC: Clinical Electrophysiology, 2023
- Flecainide in patients with arrhythmic mitral valve syndrome: A case seriesHeart Rhythm, 2022
- Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery diseaseAmerican Heart Journal, 2022
- Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathyHeart Rhythm, 2017
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991